USA – AN2 Therapeutics, Inc., a Menlo Park, CA-based clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, completed an $80m Series B redeemable convertible preferred stock financing.
The round was led by RA Capital Management, and included BVF Partners L.P., Surveyor Capital (a Citadel company), Avidity Partners, Monashee Investment Management, and Hatteras Venture Partners, who joined existing investors to complete this round. The financing is expected to support advancement of AN2’s development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).Led by Eric Easom, President and Chief Executive Officer, AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet need. The company is developing epetraborole, a once-daily oral investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM).In addition, AN2 Therapeutics also appointed two additional members to its Board of Directors, Patricia Martin and Stephanie Wong. Ms. Martin has over 25 years of biopharmaceutical leadership experience across multiple therapeutic areas and disciplines. A former Eli Lilly and Company executive, Ms. Martin was the Chief Operating Officer of Lilly Diabetes as well as Lilly’s corporate Chief Diversity Officer and Chief Alliance Officer. During her career at Lilly, she also held leadership roles in strategy, finance, clinical product development, human resources, and investor relations. Since 2019, Ms. Martin has served as the President and CEO of BioCrossroads, where she is focused on growing Indiana’s life sciences sector, through research and education, seed funds, and economic development. Ms. Martin received a B.S. in Accounting from Indiana University, an M.B.A. from Harvard Business School, and is a Certified Public Accountant (inactive) in the State of Arizona.Ms. Wong has over 20 years of finance and accounting experience in public and private companies within the biotechnology industry. Currently, Ms. Wong serves as Chief Financial Officer and Secretary of Calithera Biosciences (NASDAQ: CALA). Prior to joining Calithera, Ms. Wong served as Vice President, Finance and Controller at SciClone Pharmaceuticals and in senior finance roles at AcelRx Pharmaceuticals and Kosan Biosciences. Ms. Wong received a B.S. in Business Administration from the University of California, Berkeley and is a Certified Public Accountant (inactive) in the State of California.07/01/2022
